236 related articles for article (PubMed ID: 19158200)
1. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
Leboulleux S; Schroeder PR; Busaidy NL; Auperin A; Corone C; Jacene HA; Ewertz ME; Bournaud C; Wahl RL; Sherman SI; Ladenson PW; Schlumberger M
J Clin Endocrinol Metab; 2009 Apr; 94(4):1310-6. PubMed ID: 19158200
[TBL] [Abstract][Full Text] [Related]
2. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
[TBL] [Abstract][Full Text] [Related]
4. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
[TBL] [Abstract][Full Text] [Related]
6. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
[TBL] [Abstract][Full Text] [Related]
7. Increasing the yield of recombinant thyroid-stimulating hormone-stimulated 2-(18-fluoride)-flu-2-deoxy-D-glucose positron emission tomography-CT in patients with differentiated thyroid carcinoma.
Prestwich RJ; Viner S; Gerrard G; Patel CN; Scarsbrook AF
Br J Radiol; 2012 Oct; 85(1018):e805-13. PubMed ID: 22972977
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
Thyroid; 2005 Mar; 15(3):267-73. PubMed ID: 15785246
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
[TBL] [Abstract][Full Text] [Related]
10. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
12. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
13. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F
Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081
[TBL] [Abstract][Full Text] [Related]
15. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
17. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma.
Petrich T; Börner AR; Otto D; Hofmann M; Knapp WH
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):641-7. PubMed ID: 11976802
[TBL] [Abstract][Full Text] [Related]
18. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma.
Chin BB; Patel P; Cohade C; Ewertz M; Wahl R; Ladenson P
J Clin Endocrinol Metab; 2004 Jan; 89(1):91-5. PubMed ID: 14715833
[TBL] [Abstract][Full Text] [Related]
20. Thyroid carcinoma: iodine-131-negative whole-body scan reverses to positive after a combination of thyrogen stimulation and withdrawal.
Kasner DL; Spieth ME; Starkman ME; Zdor-North D
Clin Nucl Med; 2002 Nov; 27(11):772-80. PubMed ID: 12394123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
